CA2881075A1 - Composition with growth factors, to be used in the intranasal treatment of a neurodegenerative disease or other diseases of the central nervous system, and its method of manufacture - Google Patents

Composition with growth factors, to be used in the intranasal treatment of a neurodegenerative disease or other diseases of the central nervous system, and its method of manufacture Download PDF

Info

Publication number
CA2881075A1
CA2881075A1 CA2881075A CA2881075A CA2881075A1 CA 2881075 A1 CA2881075 A1 CA 2881075A1 CA 2881075 A CA2881075 A CA 2881075A CA 2881075 A CA2881075 A CA 2881075A CA 2881075 A1 CA2881075 A1 CA 2881075A1
Authority
CA
Canada
Prior art keywords
composition
growth
factor
nervous system
central nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2881075A
Other languages
English (en)
French (fr)
Inventor
Eduardo Anitua Aldecoa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTI Biotechnology Insttitute
Original Assignee
BTI Biotechnology Insttitute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49111229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2881075(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BTI Biotechnology Insttitute filed Critical BTI Biotechnology Insttitute
Publication of CA2881075A1 publication Critical patent/CA2881075A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CA2881075A 2012-08-09 2013-07-19 Composition with growth factors, to be used in the intranasal treatment of a neurodegenerative disease or other diseases of the central nervous system, and its method of manufacture Abandoned CA2881075A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201200810A ES2442242B1 (es) 2012-08-09 2012-08-09 Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.
ESP201200810 2012-08-09
PCT/ES2013/000176 WO2014023860A1 (es) 2012-08-09 2013-07-19 Composición con factores de crecimiento obtenidos a partir del plasma sanguíneo destinada al tratamiento de enfermedades neurodegenerativas

Publications (1)

Publication Number Publication Date
CA2881075A1 true CA2881075A1 (en) 2014-02-13

Family

ID=49111229

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2881075A Abandoned CA2881075A1 (en) 2012-08-09 2013-07-19 Composition with growth factors, to be used in the intranasal treatment of a neurodegenerative disease or other diseases of the central nervous system, and its method of manufacture

Country Status (17)

Country Link
US (2) US20140044795A1 (https=)
EP (1) EP2883569B1 (https=)
JP (1) JP6339568B2 (https=)
KR (1) KR102149162B1 (https=)
CN (1) CN104519961A (https=)
AR (1) AR092086A1 (https=)
BR (1) BR112015002760A2 (https=)
CA (1) CA2881075A1 (https=)
CL (1) CL2014003510A1 (https=)
CO (1) CO7170177A2 (https=)
ES (2) ES2442242B1 (https=)
IN (1) IN2014MN02675A (https=)
MX (1) MX357828B (https=)
PE (1) PE20150616A1 (https=)
RU (1) RU2696497C2 (https=)
TW (1) TWI649084B (https=)
WO (1) WO2014023860A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2016003282A1 (es) 2016-12-21 2017-08-18 Univ Chile Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2252993T3 (es) * 1998-12-09 2006-05-16 Chiron Corporation Administracion de agentes neurotroficos al sistema nervioso central.
AR022333A1 (es) * 1999-01-26 2002-09-04 Anitua Aldecoa Eduardo Regenerador de tejido oseo
US6811777B2 (en) * 2002-04-13 2004-11-02 Allan Mishra Compositions and minimally invasive methods for treating incomplete connective tissue repair
US7608258B2 (en) * 2002-04-13 2009-10-27 Allan Mishra Method for treatment of tendinosis using platelet rich plasma
ES2221770B2 (es) 2002-04-19 2006-07-16 Eduardo Anitua Aldecoa Metodo de preparacion de un compuesto para la regeneracion de tejidos.
US20060004189A1 (en) * 2004-07-02 2006-01-05 James Gandy Compositions for treating wounds and processes for their preparation
CA2620202C (en) * 2005-08-26 2016-10-04 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
EP2152240A4 (en) * 2007-06-08 2012-05-09 Healthpartners Res Foundation PHARMACEUTICAL COMPOSITIONS AND METHOD FOR REINFORCED TARGETING OF THERAPEUTIC COMPOUNDS TO THE CENTRAL NERVOUS SYSTEM
ES2333498B1 (es) * 2007-08-02 2011-01-10 Biotechnology Institute, I Mas D, S.L. Metodo y compuesto para el tratamiento de enfermedades o dolencias articulares o para el tratamiento de la piel con fines esteticos u otros, y el metodo de preparacion del compuesto.
EP2212344B1 (en) * 2007-09-14 2014-03-26 Formycon AG Use of slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases
MX2011011921A (es) 2009-05-14 2011-12-06 Biotechnology Inst I Mas D Sl Metodo para la preparacion de al menos un compuesto a partir de sangre, y dispositivo de extraccion para ser utilizado en la ejecucion de dicho metodo.
KR101114712B1 (ko) * 2009-10-23 2012-02-29 세원셀론텍(주) 염화칼슘용액과 제1형 콜라겐으로 혈소판풍부혈장(ｐｒｐ)을 활성화하여 조직재생을 유도하는 조성물의 제조방법
ES2369945B1 (es) 2011-07-29 2012-10-15 Eduardo Anitua Aldecoa Procedimiento de obtención de una composición que contiene factores de crecimiento a partir de un compuesto sanguíneo, y composición obtenible por dicho procedimiento.

Also Published As

Publication number Publication date
WO2014023860A1 (es) 2014-02-13
MX2015001677A (es) 2015-04-10
EP2883569A1 (en) 2015-06-17
CL2014003510A1 (es) 2015-05-04
IN2014MN02675A (https=) 2015-08-28
ES2442242B1 (es) 2014-11-25
TWI649084B (zh) 2019-02-01
BR112015002760A2 (pt) 2020-04-22
EP2883569B1 (en) 2017-12-20
ES2442242A1 (es) 2014-02-10
ES2662385T3 (es) 2018-04-06
KR102149162B1 (ko) 2020-08-31
JP2015524464A (ja) 2015-08-24
MX357828B (es) 2018-07-25
TW201408310A (zh) 2014-03-01
AR092086A1 (es) 2015-03-25
RU2015104076A (ru) 2016-09-27
US20140044795A1 (en) 2014-02-13
PE20150616A1 (es) 2015-05-25
JP6339568B2 (ja) 2018-06-06
CN104519961A (zh) 2015-04-15
CO7170177A2 (es) 2015-01-28
KR20150040860A (ko) 2015-04-15
RU2696497C2 (ru) 2019-08-02
US20160184360A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
Koerbel et al. Evolution of vestibular schwannoma surgery: the long journey to current success
Kong et al. Long-lasting restoration of memory function and hippocampal synaptic plasticity by focused ultrasound in Alzheimer's disease
BRPI0710858A2 (pt) uso de uma proteìna anti-secretora, um derivado, homólogo e/ou fragmento da mesma, tendo atividade anti-secretora, e/ou um sal farmaceuticamente ativo da mesma
Park et al. Distribution of human umbilical cord blood–derived mesenchymal stem cells (hUCB-MSCs) in canines after intracerebroventricular injection
Zweckberger et al. Synergetic use of neural precursor cells and self-assembling peptides in experimental cervical spinal cord injury
Zhou et al. Transcranial direct current stimulation alleviated ischemic stroke induced injury involving the BDNF-TrkB signaling axis in rats
Sheykhhasan et al. Plasma-rich in growth factor and its clinical application
KR20160091347A (ko) Ｐｔｅｎ 저해제를 사용한 손상된 신경의 치료
Zhong et al. Low-dose LPS modulates microglia/macrophages phenotypic transformation to amplify rehabilitation effects in chronic spinal cord injured (CSCI) mice
EP2883569B1 (en) Compositions comprising plasma growth factors for use in the treatment of neurodegenerative disorders
Lee et al. Functional recovery after injury of motor cortex in rats: effects of rehabilitation and stem cell transplantation in a traumatic brain injury model of cortical resection
RU2275924C2 (ru) Способ получения комплекса биологически активных полипептидов для нормализации функций головного мозга и фармацевтическое средство на его основе
Xie et al. Therapeutic effect of transplantation of human bone marrow‑derived mesenchymal stem cells on neuron regeneration in a rat model of middle cerebral artery occlusion
TWI327473B (en) Composition for treating a cerebrovascular disease and a method for increasing expression of erythropoietin
CN118986998A (zh) 丹参酮iia在制备臂丛神经损伤治疗药物中的应用
WO2012087180A1 (ru) Способ лечения острого нарушения мозгового и спинального кровообращения ишемического и геморрагического характера
CN106139125A (zh) 白细胞介素4在制备促进急性脑损伤后神经功能恢复药物中的用途
Dancause et al. Sensorimotor rehabilitation: At the crossroads of basic and clinical sciences
Hesse 11 Surgical Treatments
RU2808256C1 (ru) Способ персонифицированной генной терапии при угрозе ишемического инсульта головного мозга
Cioato et al. Transcranial direct current stimulation did not revert the increased central and peripheral NGF levels induced by neuropathic pain in rats
Voronova et al. Clinical Trials of Cell Products for the Treatment of Alzheimer’s Disease
Hwang et al. Stem cells ameliorate neurotrauma-induced visual disturbances and retinopathy via broad normalization of the β-catenin-related signaling pathway
Balyabin et al. Transplantation of neural progenitor cells within hyaluronic acid hydrogel in traumatic brain injury in experiment
FENG et al. Effects of butylphthalide combined with ozagrel sodium on National Institutes of Health Stroke Scale score, activities of daily living score, and coagulation function in patients with acute cerebral infarction

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180411

FZDE Discontinued

Effective date: 20220809